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A
erosol devices have been used to 
administer inhaled medications 
since the invention of modern 
mechanical ventilators. Although 
many new aerosol devices are available for 
ventilator-dependent patients, successful 
aerosol therapy still depends on thorough 
clinician knowledge of aerosol devices and 
their proper use. This paper explains the 
types of aerosol devices available on the 
market and provides strategies for choos-
ing the right device for optimal treatment of 
mechanically-ventilated patients. 
Description of Aerosol Delivery 
Devices
Nebulizers: Jet, ultrasonic and mesh 
nebulizers are used for aerosol drug delivery 
by converting liquid medications into small 
droplets that can be inhaled into the lower 
respiratory tract of ventilator-dependent 
patients.
To aerosolize liquid medications, jet 
nebulizers use a jet of compressed air or 
oxygen to draw on a reservoir and shear the 
liquid into particles. Jet nebulizers are wide-
ly used for ventilator-dependent patients 
because they are inexpensive and easy to use. 
Ultrasonic nebulizers are powered by 
electricity or battery to generate high fre-
quency vibrations with a piezo, thus creat-
ing a standing wave in the medication and 
aerosols at the crest of the wave.1,2 Unlike jet 
nebulizers, they do not add gas to the venti-
lator circuit, rather, aerosol particle size and 
drug output are affected by the frequency 
and amplitude of vibration of the piezo-
electric crystal. Aerosol particle size is in-
versely related to the vibration frequency of 
the piezo-electric crystal, while drug output 
is directly related to the amplitude of crystal 
vibration.3,4
The mesh nebulizer, also operated by 
electricity or battery, vibrates a piezo that 
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moves liquid formulations through a fine 
mesh to generate aerosol.1,2,5 The mesh neb-
ulizer is a single-use device with a vibrating 
aperture plate designed to deliver aerosol-
ized medications to mechanically-ventilated 
patients. The nebulizer is compatible with 
conventional ventilators. Because the mesh 
nebulizer operates without compressed gas, 
it does not change ventilator parameters 
and the reservoir of the nebulizer can be re-
filled without interrupting ventilation. Fur-
thermore, mesh nebulizers are easy to use 
and have a higher rate of drug output than 
jet nebulizers.  Unlike ultrasonic nebulizers, 
they do not affect the temperature or con-
centration of the solution being delivered.6 
As with other new nebulizers, mesh 
nebulizer designs are portable, handheld, 
and highly efficient with low residual vol-
ume.1,2,5 They also have a silent operation 
and rapid output. Also, solutions, proteins 
and liposomal formulations can be nebu-
lized by mesh nebulizers. Because of these 
advantages, mesh nebulizers are likely be-
come popular for delivering aerosols to ven-
tilator-dependent patients. Whereas in vitro 
studies have shown mesh nebulizers to be 
efficient  in aerosol delivery during mechan-
ical ventilation,7,8 more clinical information 
about them is needed.
Pressurized Metered-Dose Inhalers 
(pMDIs): The pMDI is the most commonly 
used aerosol device for inhalation therapy 
worldwide; it is a compact and portable de-
vice that is easy to operate with short treat-
ment time, multi-dose convenience and 
good dose consistency.9-11 The basic compo-
nents of a pMDI include a canister, propel-
lants, drug formulation, metering valve and 
actuator. A pressurized mixture of propel-
lants, surfactants, preservatives and active 
drug is released from the metering valve of 
the canister, which fits into an actuator boot.
Two types of propellants are used with 
pMDIs: (1) chlorofluorocarbon (CFC) and 
(2) hydrofluoroalkane (HFA). HFA-pMDIs 
are different from CFC-pMDIs in terms of 
the formulation, metering-valve and actua-
tor design.54,9 For example, HFAs contain 
ethanolic solutions while CFCs use a sur-
factant for dispersion. HFAs have a softer 
and finer aerosol spray with greater lung 
deposition than CFCs.12-14 However, despite 
differences in the pMDI formulations, HFA-
pMDIs are similar to those of CFC pMDIs, 
in terms of bronchodilator response,15,16 
pulmonary function17,18 and side effects.19
A variety of spacers are used for aerosol 
drug delivery in mechanically-ventilated pa-
tients. However, electrostatic charge and the 
type of spacer need to be considered. The 
electrostatic charge decreases aerosol deliv-
ery by drawing small particles to the walls 
of the chamber; therefore, clinicians need 
to review the electrostatic properties of the 
spacer before treatment. Spacers are made 
of metal, paper or plastic, each of which 
have different electrostatic properties. Elec-
trostatic charge is not an issue with metal or 
paper spacers, but plastic spacers may have 
electrostatic or non-electrostatic properties. 
If a plastic spacer with electrostatic proper-
ties is used for aerosol therapy, clinicians 
should wash it with liquid detergent to re-
duce the electrostatic charge before treat-
ment. Actuating the pMDI 12 or 20 times 
into a spacer also reduces the electrostatic 
charge. However, many pMDI doses are 
wasted with this technique, and it is less ef-
fective than washing.20,21 
Types of spacers include unidirectional, 
bidirectional and cylindrical/reservoir adap-
tors. The spacer type influences the efficien-
cy of aerosol delivery during mechanical 
ventilation.9,22-24 While bidirectional spac-
ers are superior to unidirectional spacers in 
dose delivery, cylindrical spacers have been 
shown to have 4-to-6 fold greater efficiency 
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on aerosol delivery than unidirectional and 
bidirectional spacers that attach directly to 
the endotracheal tube (ETT).25-27  
Issues with Aerosol Delivery Devices
Problems with Nebulizers: Jet nebuliz-
ers are bulky. They require a compressor or 
pressurized gas to operate, and are labor-
intensive.20,28,29 They are also less efficient 
than other aerosol devices and retain a lot of 
the medication in the nebulizer cup, limit-
ing the drug available to the patient. They 
require more preparation to setup, and 
more time for cleaning and maintenance 
than pMDIs. Further, the additional gas 
flow delivered into the ventilator circuit 
may change the set flow and delivered vol-
ume and require adjustments of alarm set-
tings both during and after nebulization 
if the ventilator does not compensate for 
nebulizer gas flow entering the circuit. This 
is especially important in ventilator-depen-
dent children because they are affected to 
a greater extent when extra flow is added 
to the ventilator circuit. Clinicians should 
exercise caution when changing ventilator 
parameters and return to them to pretreat-
ment levels after the treatment is completed. 
Since jet nebulizers are attached to the ven-
tilator circuit with a standard T adaptor, at-
taching or removing the nebulizer from the 
ventilator circuit may interrupt ventilation. 
Therefore, valved T adaptors should be used 
in order to allow placement and removal of 
the jet nebulizer without loss of pressure in 
the ventilator circuit. 
Ultrasonic nebulizers also have several 
problems. They are bulky and more expen-
sive than jet nebulizers. Their particle size is 
larger than with jet nebulizers, and drug so-
lutions used with ultrasonic nebulizers be-
come more concentrated during operation. 
There is an increase in solution temperature 
after a few minutes of operation, and as a 
result, ultrasonic nebulizers may denature 
some drug formulations. Although smaller 
ultrasonic nebulizers are used to deliver 
aerosolized drugs to mechanically-ventilat-
ed patients,30 the cost and size of these nebu-
lizers make them less desirable, in addition 
to their inefficiency in nebulizing drug sus-
pensions and more viscous solutions.31,32 
Therefore, ultrasonic nebulizers are not 
widely used for aerosol delivery during me-
chanical ventilation. 
Mesh nebulizers are more expensive 
than jet nebulizers. Suspension or viscous 
drugs may clog the pores of the mesh nebu-
lizer which may not be easily detectible by 
the output of the nebulizer.33 Cleaning of 
mesh nebulizers should be gentle in order 
to prevent damage to the mesh. 
When a nebulizer is used with mechan-
ically-ventilated patients, escape of aerosol 
to the environment creates health risks to 
healthcare providers and bystanders.34 Oth-
er problems associated with nebulizers are 
infection due to contamination (jet nebu-
lizer) and increases in drug concentration in 
the nebulizer cup when using jet and ultra-
sonic nebulizers.
Problems with pMDIs: If a dose coun-
ter is not used with a pMDI, it is difficult to 
determine the dose left in the pMDI. Thus, 
pMDIs may be used beyond their capac-
ity or remaining doses may be wasted. The 
dose counters, which are attached to the top 
or boot of the pMDI, are manufactured by 
different companies. Although use of dose 
counters is recommended with all pMDIs, 
it should be noted that newer pMDIs with 
dose counters may not permit removal of 
the canister from the actuator. In this case, 
the actuator itself must fit an adapter to be 
connected to the ventilator circuit, but the 
efficiency of such systems is not known. In-
tegrating dose counters into new pMDIs is 
required by the FDA in order to determine 
the total number of doses available in the 
device.35 
Selection of an Aerosol Device for 
Mechanically-Ventilated Patients 
Nebulizers or pMDIs with in-line spac-
ers are used to administer inhaled medica-
tions during mechanical ventilation. Both 
nebulizers and pMDIs produce similar 
therapeutic effects in mechanically-venti-
lated patients.4,22,36-38 The therapeutic aim 
and availability of the drug generally de-
termine which aerosol device to use. pM-
DIs are preferred for inhalation therapy in 
ventilator-dependent patients because of 
problems associated with use of nebulizers 
and the advantages of pMDI, such as con-
venience, lower cost and decreased risk of 
damaging the flow sensor.4,39 However, only 
a few drug formulations are available as 
pMDIs. Therefore, they are mainly used to 
deliver bronchodilators and corticosteroids 
for ventilator-supported patients with air-
way obstruction,22,23,40 while nebulizers are 
used to deliver a variety of drugs such as 
bronchodilators, corticosteroids, antibiotics, 
prostaglandins, surfactant, mucolytic agents 
and other formulations that are not avail-
able as pMDIs. A few studies have shown 
that use of pMDIs with ventilator-depen-
dent patients has increased significantly 
over the years 41,42 because of their conve-
nience, more consistent dosing and reduced 
chances of bacterial contamination.43,44 
Factors Affecting Aerosol Drug 
Delivery During Mechanical 
Ventilation
Aerosol delivery during mechani-
cal ventilation depends on several factors. 
These can be divided into three categories: 
(1) ventilator-related factors, (2) circuit-re-
lated factors and (3) device-related factors.45
Ventilator-related Factors: Ventilator-
related factors such as inspiratory flow rate, 
ventilator mode, inspiratory time, tidal 
volume, bias flow and wave patterns make 
a significant difference in aerosol drug de-
livery to ventilator-dependent patients. The 
lower the flow, the greater the amount of 
aerosol delivered to the patient. Since high 
inspiratory flow rates increase turbulent 
flow and inertial impaction of aerosol par-
ticles, aerosol deposition with high inspira-
tory flow rates is less than with lower flow 
rates. Peak flow rates of 40-50 L/min may be 
used to improve drug delivery during me-
chanical ventilation as long as this is toler-
ated by the patient.46,47 
For critically ill patients with low com-
pliance and low resistance, aerosol delivery 
through a nebulizer is more efficient with 
volume-controlled ventilation than pres-
sure-controlled ventilation.48 This is not the 
case with pMDIs. Also, it has been shown 
that spontaneous ventilation modes such as 
continuous positive airway pressure (CPAP) 
increase aerosol delivery by 30% compared 
to controlled breaths of equivalent tidal 
volume.49 Nebulizers generate aerosol over 
time; therefore, using a longer inspiratory 
time increases the efficiency of nebuliz-
ers, in contrast, pMDIs, which have a short 
aerosol generation time, are not influenced 
by the duration of inspiratory time. 
Tidal volume (Vt) is directly related 
to aerosol deposition. Although setting Vt 
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greater than 500 ml in an adult improves 
aerosol drug delivery during mechanical 
ventilation,47,49 larger Vt can damage the 
lungs of mechanically-ventilated patients. 
Vt may be a problem when it is not adequate 
to move the aerosol from the generator to 
the end of the patient airway in a single 
breath; therefore, it is important to set the 
Vt larger than the volume of the ventilator 
circuit and artificial airway in order to in-
crease aerosol delivery. 
Although descending ramp wave pat-
terns provide higher efficiency than square 
wave patterns at the same peak flow, the ef-
fect of inspiratory waveform is much less in 
pMDIs than in nebulizers.48 Bias flow, also 
known as trigger sensitivity, affects the effi-
ciency of nebulizers during mechanical ven-
tilation. Increasing bias flow from 2 to 5 L/
min decreases aerosol deposition in ventila-
tor-dependent patients by diluting aerosols 
and increasing the washout into the expira-
tory limb between breaths.8 
Circuit-related Factors: Using heat-
moisture exchangers (HMEs) or heated 
humidifiers, the gas in the ventilator circuit 
is heated and humidified in order to avoid 
drying the airway mucosa. Since the filter in 
the HME is considered a barrier to aerosol 
delivery, it should not be placed between 
the aerosol device and the patient. Also, if 
a dry circuit is used, aerosol therapy should 
be completed in 15 minutes to minimize the 
effects of dry gas on the airway mucosa.40
As shown in Figure 1, some HMEs de-
signed for aerosol delivery (HME-AD) allow 
inhalation therapy without removing the 
HME-AD from the circuit during mechani-
cal ventilation. Although the designs of these 
HME-ADs are different, each HME-AD has 
two configurations: (1) an HME configura-
tion that functions like a regular HME, and 
(2) an aerosol configuration in which inspi-
ratory gas bypasses the HME to deliver in-
haled medications to ventilator-dependent 
patients. It has been reported that drug de-
livery varies with HME-ADs because of the 
design and composition of the HME-ADs,50 
but clinical research is needed to determine 
the in-vivo efficiency of aerosol delivery by 
different HME-ADs and the effectiveness of 
HME-ADs with different aerosol devices.
Several in-vitro studies have shown 
up to 50% reduction in aerosol delivery 
with heated/humidified ventilator cir-
cuits.7,22,49,51-54 However, bypassing the 
humidifier and exposing a ventilator-de-
pendent patient to dry and cold gas just to 
increase aerosol deposition is not recom-
mended. Clinicians can increase the effi-
ciency of aerosol therapy by paying atten-
tion to the technique of administration and 
increasing the dose when a heated humidi-
fier is used. 
The density of gas used with the venti-
lator has been shown to make a substantial 
difference in aerosol delivery. For instance, 
helium-oxygen mixtures greater than 50% 
increase aerosol delivery with nebulizers 
and pMDIs more than air or air-oxygen 
mixtures used to ventilate the patient.55 
Aerosol deposition with artificial air-
ways such as an endotracheal tube (ETT) or 
tracheostomy tube (TT) has not been stud-
ied much. Also, research on the efficiency of 
aerosol delivery in intubated patients has fo-
cused largely on ETT, with little analysis of 
effect of TT on aerosol delivery during me-
chanical ventilation. Since ETTs are narrow-
er than the internal diameter of the trachea, 
they are associated with increased airway 
resistance and losses in aerosol delivery.56,57 
Previous in-vitro studies indicate that there 
is no difference in aerosol deposition be-
tween ETT with 9.0 -7.0 mmID, but aerosol 
delivery to ventilator-dependent patients is 
reduced as the inner diameter of ETT de-
creases from 6.0 mmID to 3.0 mmID.52,56
Device-related Factors: The nebulizer 
type and its position in the ventilator circuit 
have all been shown to impact the efficiency 
of aerosol delivery. Previous research re-
ported variations in dose efficiency in differ-
ent brands of nebulizers, and different units 
of the same brand.58,59 Since fill volume and 
nebulizer type affect drug delivery,57,60 fol-
lowing instructions in the drug/device label 
is critical. 
Optimum Technique for Drug Delivery 
in Ventilator-Dependent Patients
Aerosol drug delivery to ventilator-
dependent patients is affected by many 
factors. Understanding these factors has 
helped us to develop optimal techniques for 
using pMDIs and nebulizers. When proper 
administration technique is used, aerosol 
therapy in mechanically-ventilated patients 
is safe, convenient and effective. Figure 2 
outlines the optimum administration tech-
nique with nebulizers and pMDIs. 
Patient position: Studies have shown 
that drug delivery to patients in a semi-fowl-
er and sitting position produces a significant 
response.61-65 Therefore, if the patient can-
not sit in the bed during inhalation therapy, 
a semi-fowler position with the head of the 
bed elevated to 20° to 30° above the hori-
zontal should be used for aerosol adminis-
tration during mechanical ventilation. 
Optimum Technique with Nebulizers: 
Jet nebulizers are operated continuously by 
pressurized gas or intermittently by a sepa-
rate line connected to the ventilator which 
provides driving pressure and flow to the 
nebulizer. During intermittent operation 
(aka nebulizer function on the ventilator), 
the ventilator operates the nebulizer only in 
inspiration, thus reducing aerosol loss dur-
ing expiration. When nebulizer function is 
used for aerosol therapy during mechanical 
ventilation, the ventilator compensates for 
the flow to the nebulizer to maintain con-
stant tidal volume and minute ventilation. 
Although jet nebulizers are often operated 
continuously, it has been shown that inter-
mittent nebulization increases aerosol depo-
sition more than continuous nebulization 
during mechanical ventilation.51,66 However, 
it must be noted that the lower pressure of 
the driving gas may affect the aerosol char-
acteristics and delivery efficiency of a nebu-
lizer operated through the ventilator. For 
instance, operating a nebulizer with a lower 
driving pressure (<15 psi) through a venti-
lator instead of using pressurized gas (≥50 
psi) may generate larger particles and de-
crease the efficiency of the nebulizer.40  How-
ever, it has been reported that the newer 
Figure 1. HMEs designed for aerosol delivery during mechanical ventilation. A: Circuvent HME/HCH bypass (Smiths-Medi-
cal Keene, NH )with Gibeck Humidvent Filter Light S inline (Hudson RCI, Arlington Heights, IL).  B: Humid-Flo HME (Hudson 
RCI, Arlington Heights, IL).  C: Airlife bypass HME (Carefusion, San Diego, California). (Reproduced with permission, from 
Reference 70)
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ventilators with built-in nebulizer function 
deliver reproducible and consistent doses to 
ventilator-dependent patients.51,67 
When the jet nebulizer is placed closer 
to the ventilator and operated continuously 
under heated/humidified conditions, the 
aerosol tubing acts as a reservoir because 
continuous output of the jet nebulizer 
charges the inspiratory limb of the ventilator 
circuit between inspiration and minimizes 
aerosol loss during the expiratory phase of 
the breathing cycle.7 pMDIs, mesh and ul-
trasonic nebulizers that do not add gas flow 
to the ventilator circuit appear to be most 
efficient when placed in the inspiratory limb, 
6 inches from the Y adaptor.7 With the addi-
tion of continuous bias flow in the ventilator 
circuit, placement of aerosol generators near 
the ventilator may be more efficient.8 
Optimum Technique with pMDIs: 
Priming and shaking the canister before 
treatment is important, especially prior to 
first use and when the canister has not been 
used for more than 24 hours. Otherwise, the 
drug in the pMDI formulation may separate 
from the propellants, which reduces aerosol 
delivery.68 Also, synchronizing pMDI ac-
tuation with the beginning of inspiration is 
required for effective aerosol therapy dur-
ing mechanical ventilation. Aerosol drug 
delivery to ventilator-dependent patients is 
maximized by synchronizing the actuation 
of pMDI with the beginning of inspira-
tion.69 When a spacer is used with a venti-
lator-dependent patient, it should be placed 
at approximately 15 cm from the ETT in or-
der to achieve a significant bronchodilator 
response.24,61
Patient Monitoring: In order to elimi-
nate the complications caused by aerosol 
treatment, some institutions require respi-
ratory therapists to stay in the room when 
administering aerosol therapy through 
nebulizers. Although this increases respira-
tory therapist time spent with patients, such 
practice assures not only patient safety but 
also effective aerosol therapy for critically-ill 
patients.
Conclusion
In conclusion, there have been dra-
matic advances in aerosol drug delivery for 
ventilator-dependent patients over the years. 
However, aerosol therapy during mechani-
cal ventilation is still complex because of 
challenges associated with the aerosol de-
vices, inhaled medications, device selection 
and administration technique. Therefore, 
understanding aerosol delivery devices, po-
tential problems and factors influencing 
drug delivery to mechanically-ventilated 
patients is crucial for the safety and effec-
tiveness of aerosol therapy for patients in 
the ICU.
Figure 2. An algorithm describing steps for optimal drug administration 
technique by each aerosol generator (Reproduced with permission from 
Reference 45).
Review order identify patient and assess need for bronchodilator. 
Clear the airways by suctioning, if needed.
If using an HME, remove it from the circuit. If using a heated 
humidifier, do not turn off or disconnect during the treatment.
JN:
Correctly assemble the 
nebulizer.
Fill the nebulizer with volume 
on drug label. You may 
increase volume to 4-6 mL to 
increase delivery.
Place the JN in the inspiratory 
line near the “Y” adapter or 
proximal to the ventilator.
VMN:
Correctly assemble the 
nebulizer.
Pour recommended drug 
volume into the nebulizer.
Place the VMN in the 
inspiratory line near the “Y” 
adapter.
pMDI:
Shake and prime the pMDI.
Warm the pMDI canister to 
hand or body temperature.
Place the pMDI 
spacer/adapter in the 
inspiratory line near the “Y” 
adapter.
Correctly assemble the pMDI 
canister with spacer/adapter.
Ensure that there is no leak in the circuit.
Position the patient in an upright position, if possible.
JN:
Connect the nebulizer to a 
power source.
Use gas source on the 
ventilator in order to 
synchronize the nebulization 
with inspiration, if 
appropriate.
Otherwise set gas flow on the 
JN at 6 to 8 l/min (or flow 
recommended on label).
VMN:
Connect the nebulizer to a 
power source.
Turn on the power
pMDI:
Coordinate actuations with 
beginning of inspiration.
Do not remove or shake the 
pMDI between actuations.
Wait 15 seconds between 
actuations
Observe aerosol cloud for adequate aerosol generation during 
treatment
At the completion of treatment, remove device from the ventilator 
circuit.
Reconnect the HME.
Return ventilator settings and alarms to previous values. Ensure 
there is no leak in the ventilator circuit.
Monitor vital signs, oxygen saturation and patient-ventilator 
synchronization.
Monitor for adverse response.
Assess outcome and document findings.
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